ArticleASN neuro2026
SP1 Aggravates Neonatal Hypoxic-Ischemic Brain Damage by Promoting Ferroptosis Through Transcriptional Upregulation of ACSL4.
Article in ASN neuro, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Neonatal hypoxic-ischemic brain damage (HIBD) is a major cause of neurological disability. This study investigated the role of the transcription factor specificity protein 1 (SP1) and its target, Acyl-CoA Synthetase Long-Chain Family Member 4 (ACSL4), in regulating ferroptosis in neonatal HIBD. Using a neonatal mouse HIBD model and an in vitro neuronal oxygen-glucose deprivation/reperfusion (OGD/R) model, we applied gene knockdown/overexpression and pharmacological tools, analyzed via molecular and histological techniques. Ferroptosis was activated in HIBD. Hypoxic-ischaemic injury upregulated SP1, which transcriptionally activated ACSL4 by binding its promoter. SP1 knockdown attenuated neuronal and brain injury, reducing lipid peroxidation and iron accumulation while improving cell viability and cognitive function. These protections were abolished by ACSL4 overexpression or erastin co-treatment, and were associated with suppression of the ACSL4-dependent ferroptotic pathway. The SP1/ACSL4 axis critically aggravates neonatal hypoxic-ischaemic brain damage by promoting ferroptosis, representing a promising therapeutic target.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.